Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors
Éolia Brissot(Inserm), Mohamad Mohty(Sorbonne Université), Éric Deconinck(European Union), Didier Blaise(Institut Paoli-Calmettes), Fabio Ciceri(Vita-Salute San Raffaele University), Jaime Sanz(Hospital Universitari i Politècnic La Fe), Myriam Labopin(Sorbonne Université), Claude‐Eric Bulabois(Centre Hospitalier Universitaire de Grenoble), Sebastian Giebel(The Maria Sklodowska-Curie National Research Institute of Oncology), Riitta Niittyvuopio, Stephan Mielke(Karolinska University Hospital), Arnon Nagler(Sheba Medical Center), Jan J. Cornelissen(Erasmus MC), Martin Mistrík(Radboud University Nijmegen), Laimonas Griškevičius(Vilnius University), Annalisa Ruggeri(Inserm), Bipin N. Savani(Vanderbilt University Medical Center), Édouard Forcade(Hôpital Cardiologique du Haut-Lévêque), Gwendolyn Van Gorkom(Maastricht University Medical Centre), Ellen Meijer(Hospital General Universitario Gregorio Marañón), И.А. Моисеев(First Pavlov State Medical University of St. Petersburg), Montserrat Rovira(Humanitas University), Alexandros Spyridonidis(General University Hospital of Patras)
Cited by 68
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Gene Therapy for Immunodeficiency Due to Adenosine Deaminase Deficiency
|New England Journal of Medicine|2009|1k
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
|New England Journal of Medicine|2020|859